Loading...
Market
Will FastGlioma receive FDA approval for clinical use by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA official announcements and press releases
Story
AI Tool FastGlioma Detects Brain Tumors in Seconds with 92% Accuracy During Surgery
Nov 14, 2024, 07:51 AM
Researchers at the University of Michigan (UMich) and UCSF have developed an AI tool called FastGlioma that can detect brain tumor boundaries in real-time during surgery with 92% accuracy. This innovative technology identifies remaining brain tumor tissue in just 10 seconds, significantly outperforming traditional methods that miss nearly 25% of residual tumors. The AI model, validated in a prospective multi-center trial and made open-source, provides a visual foundation for intraoperative brain surgery, enabling accurate detection of glioma infiltration without the need for labels. Published in Nature and validated by ToddCHollon, this breakthrough addresses a critical challenge in glioma treatment, offering real-time guidance to surgeons and potentially improving surgical outcomes.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Accelerated Approval • 25%
Full Approval • 25%
Conditional Approval • 25%
No Approval • 25%
Approved by FDA • 25%
Approved by EMA • 25%
Approved by both FDA and EMA • 25%
Not approved • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
